AI assistant
ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2017
Aug 3, 2017
33882_dirs_2017-08-03_7757e5c9-c9e9-4c79-bf9e-aed3df350c02.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK: 0000949858
Period of Report: 2017-08-01
Reporting Person: Cormack Scott Daniel (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-08-01 | Common Stock | M | 3125 | $0.00 | Acquired | 16302 | Direct |
| 2017-08-01 | Common Stock | M | 1590 | $0.00 | Acquired | 9685 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-08-01 | Restricted Stock Unit (RSU) | $ | M | 568 | Disposed | 2018-04-13 | Common Stock (568) | Direct |
| 2017-08-01 | Restricted Stock Unit (RSU) | $ | M | 1705 | Disposed | 2019-06-18 | Common Stock (1705) | Direct |
| 2017-08-01 | Restricted Stock Unit (RSU) | $ | M | 852 | Disposed | 2018-06-12 | Common Stock (852) | Direct |
| 2017-08-01 | Restricted Stock Unit (RSU) | $ | M | 284 | Disposed | 2018-04-13 | Common Stock (284) | Indirect |
| 2017-08-01 | Restricted Stock Unit (RSU) | $ | M | 852 | Disposed | 2019-06-18 | Common Stock (852) | Indirect |
| 2017-08-01 | Restricted Stock Unit (RSU) | $ | M | 454 | Disposed | 2018-06-12 | Common Stock (454) | Indirect |
| 2017-08-01 | Stock Option (right to buy) | $4.57 | A | 11000 | Acquired | 2027-08-01 | Common Stock (11000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $245.08 | 2019-12-31 | Common Stock (2272) | 2272 | Direct |
| Stock Option (right to buy) | $175.67 | 2020-12-14 | Common Stock (3636) | 3636 | Direct |
| Stock Option (right to buy) | $143.00 | 2022-05-08 | Common Stock (3409) | 3409 | Direct |
| Stock Option (right to buy) | $131.45 | 2023-03-12 | Common Stock (3409) | 3409 | Direct |
| Stock Option (right to buy) | $129.69 | 2024-03-14 | Common Stock (4545) | 4545 | Direct |
| Stock Option (right to buy) | $20.46 | 2025-05-19 | Common Stock (6818) | 6818 | Direct |
| Stock Option (right to buy) | $156.20 | 2020-06-08 | Common Stock (318) | 318 | Indirect |
| Stock Option (right to buy) | $185.13 | 2021-01-03 | Common Stock (3181) | 3181 | Indirect |
| Stock Option (right to buy) | $143.00 | 2022-05-08 | Common Stock (1363) | 1363 | Indirect |
| Stock Option (right to buy) | $131.45 | 2023-03-12 | Common Stock (1818) | 1818 | Indirect |
| Stock Option (right to buy) | $129.69 | 2024-03-14 | Common Stock (2272) | 2272 | Indirect |
| Stock Option (right to buy) | $20.46 | 2015-05-19 | Common Stock (3409) | 3409 | Indirect |
Footnotes
F1: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. On August 1, 2017, the effective date of the merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. (the "Merger"), the closing price of Achieve Life Sciences, Inc.'s common stock was $4.576 per share, representing a closing price of $0.416 per share of Oncogenex common stock as adjusted to reflect an 11-to-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split").
F2: Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement.
F3: Pursuant to the terms of the reporting holder's employment agreement, the RSUs immediately vested in full on August 1, 2017, in connection with the consummation of the Merger.
F4: Reflects the Reverse Stock Split.
F5: Pursuant to the terms of the reporting holder's spouse's consulting agreement, the RSU immediately vested on August 1, 2017, in connection with the consummation of the Merger.